Previous Next Index Thread

CDC AIDS Daily Summary 06/28/96

                      AIDS Daily Summary 
                        June 28, 1996
 The Centers for Disease Control and Prevention (CDC) National 
 AIDS Clearinghouse makes available the following information as a 
 public service only. Providing this information does not 
 constitute endorsement by the CDC, the CDC National AIDS 
 Clearinghouse, or any other organization. Reproduction of this 
 text is encouraged; however, copies may not be sold, and the CDC 
 National AIDS Clearinghouse should be cited as the source of this 
 information. Copyright 1996, Information, Inc., Bethesda, MD
 "AMA Backs Mandatory HIV Testing of Pregnant Women and Newborns" 
 "FDA Clears Drug to Treat Blindness in AIDS Patients"
 "New Blood Treatment May Help Fight AIDS"
 "Doctors Discover New Worm, One That's Lethal to Humans" 
 "HIV Infections on the Rise in Japan"
 "STD Expert Says CDC's Gonorrhea Guidelines Are Outdated" 
 "Restricted Expression of KS-Associated HHV8 Found in KS Tissue" 
 "Bacterial Infections Associated With HIV-Related Oral Lesions" 
 "Test Case"
 "Public Spending on AIDS"
 "AMA Backs Mandatory HIV Testing of Pregnant Women and Newborns" 
 Washington Post (06/28/96) P. A2
      In a surprising reversal on a controversial issue, the
 American Medical Association announced Thursday the 
 organization's endorsement of mandatory HIV testing for all 
 pregnant women and newborns.  The group had advocated voluntary 
 testing because doctors did not have the tools to treat pregnant 
 women with HIV.  This changed, however, with the discovery that 
 AZT can markedly reduce the risk of transmitting the virus to the 
 child.  Opponents to mandatory testing, including AIDS activists, 
 civil libertarians, and some mothers, argued that testing would 
 lead to discrimination.  Many doctors also argued that mandatory 
 testing would drive the women most at risk away from medical 
 care.  The AMA's decision does not carry legal weight, but the 
 group's policies do influence lawmakers.
 "FDA Clears Drug to Treat Blindness in AIDS Patients" 
 Wall Street Journal (06/28/96) P. B3
      The Food and Drug Administration has approved Gilead
 Sciences' drug Vistide as a treatment for cytomegalovirus, a 
 virus that causes blindness in AIDS patients.  The drug is 
 Gilead's first commercial product.  Analysts have predicted that 
 the approval could lead to approximately $45 million of sales 
 over the next year.  Gilead, which has been investing heavily in 
 research and development, had a net loss of $10.8 million, or 42 
 cents a share, on sales of $779,000 in the first quarter.  The 
 company's stock rose 75 cents, to $23.75, in Nasdaq Stock Market 
 "New Blood Treatment May Help Fight AIDS" 
 Washington Times (06/28/96) P. A3
      Researchers at the Naval Medical Research Center reported 
 Thursday that a new preliminary experiment has allowed them to 
 produce a large number of immune cells that seem to resist HIV in 
 the laboratory.  Carl June and colleagues report their results in